gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Blinatumomab binds CD3 on T cells to activate them and link to CD19+ cells; the T cells then kill CD19+ targets via perforin/granzyme. CD3+ cells are not directly killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
CD3 T-cell receptor complex (specific chain not specified in trial summary)
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05645718
disease_id_num_tar_ref
1679
drug_id_num_tar_ref
4541